

Characteristics and management of rash following lenalidomide and rituximab in patients with untreated indolent non-Hodgkin lymphoma

Nathan H. Fowler, Loretta J. Nastoupil, Frederick B. Hagemeister, Sattva S. Neelapu, Luis E. Fayad, Denise LeBlanc, Felipe Samaniego, and Chan Yoon Cheah

Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd Houston, TX, USA

Correspondence: nfowler@mdanderson.org

doi:10.3324/haematol.2015.131144

Supplemental File for: Fowler et al. Characteristics and management of rash following lenalidomide and rituximab in patients with untreated indolent non-Hodgkin lymphoma

Grade	Definition
1	Macular or papular eruption without associated symptoms
2	Macular or papular eruption with pruritus or associated symptoms; localized desquamation or other lesions covering <50% of BSA
3	Severe, generalized erythroderma or macular, papular or vesicular eruption; desquamation covering ≥50% BSA
4	Generalized exfoliative, ulcerative or bullous dermatitis
5	Death

Supplemental Table 1. CTCAE version 3.0 grading for dermatologic toxicity (rash/desquamation)¹³.

BSA, body surface area.